02126.HK
JW (Cayman) Therapeutics Co. Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 2.20
+0.46%Margins
Gross margin
39.8%
EBITDA margin
-67.3%
EBIT margin
-95.0%
Net margin
-116.8%
FCF margin
-27.5%
-73.8%
Return on equity
-40.1%
Return on assets
-38.4%
Return on invested capital
0.31x
Asset turnover
-HKD 89.8M
Cash from operations
HKD 1.10
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026